1094 related articles for article (PubMed ID: 29736744)
21. (R)-Ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anaesthetic doses.
Zanos P; Highland JN; Liu X; Troppoli TA; Georgiou P; Lovett J; Morris PJ; Stewart BW; Thomas CJ; Thompson SM; Moaddel R; Gould TD
Br J Pharmacol; 2019 Jul; 176(14):2573-2592. PubMed ID: 30941749
[TBL] [Abstract][Full Text] [Related]
22. Beyond Ketamine: New Approaches to the Development of Safer Antidepressants.
Chaki S
Curr Neuropharmacol; 2017; 15(7):963-976. PubMed ID: 28228087
[TBL] [Abstract][Full Text] [Related]
23. Loss of parvalbumin-immunoreactivity in mouse brain regions after repeated intermittent administration of esketamine, but not R-ketamine.
Yang C; Han M; Zhang JC; Ren Q; Hashimoto K
Psychiatry Res; 2016 May; 239():281-3. PubMed ID: 27043274
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms of ketamine and its metabolites as antidepressants.
Hess EM; Riggs LM; Michaelides M; Gould TD
Biochem Pharmacol; 2022 Mar; 197():114892. PubMed ID: 34968492
[TBL] [Abstract][Full Text] [Related]
25. The role of eEF2 kinase in the rapid antidepressant actions of ketamine.
Suzuki K; Monteggia LM
Adv Pharmacol; 2020; 89():79-99. PubMed ID: 32616215
[TBL] [Abstract][Full Text] [Related]
26. Pharmacotherapy: Ketamine and Esketamine.
Feeney A; Papakostas GI
Psychiatr Clin North Am; 2023 Jun; 46(2):277-290. PubMed ID: 37149345
[TBL] [Abstract][Full Text] [Related]
27. Synaptic mechanisms underlying rapid antidepressant action of ketamine.
Kavalali ET; Monteggia LM
Am J Psychiatry; 2012 Nov; 169(11):1150-6. PubMed ID: 23534055
[TBL] [Abstract][Full Text] [Related]
28. The Glutamatergic System in Treatment-Resistant Depression and Comparative Effectiveness of Ketamine and Esketamine: Role of Inflammation?
Halaris A; Cook J
Adv Exp Med Biol; 2023; 1411():487-512. PubMed ID: 36949323
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
Daly EJ; Trivedi MH; Janik A; Li H; Zhang Y; Li X; Lane R; Lim P; Duca AR; Hough D; Thase ME; Zajecka J; Winokur A; Divacka I; Fagiolini A; Cubala WJ; Bitter I; Blier P; Shelton RC; Molero P; Manji H; Drevets WC; Singh JB
JAMA Psychiatry; 2019 Sep; 76(9):893-903. PubMed ID: 31166571
[TBL] [Abstract][Full Text] [Related]
30. NMDAR inhibition-independent antidepressant actions of ketamine metabolites.
Zanos P; Moaddel R; Morris PJ; Georgiou P; Fischell J; Elmer GI; Alkondon M; Yuan P; Pribut HJ; Singh NS; Dossou KS; Fang Y; Huang XP; Mayo CL; Wainer IW; Albuquerque EX; Thompson SM; Thomas CJ; Zarate CA; Gould TD
Nature; 2016 May; 533(7604):481-6. PubMed ID: 27144355
[TBL] [Abstract][Full Text] [Related]
31. Effects of Mu-Opiate Receptor Gene Polymorphism rs1799971 (A118G) on the Antidepressant and Dissociation Responses in Esketamine Nasal Spray Clinical Trials.
Saad Z; Hibar D; Fedgchin M; Popova V; Furey ML; Singh JB; Kolb H; Drevets WC; Chen G
Int J Neuropsychopharmacol; 2020 Dec; 23(9):549-558. PubMed ID: 32367114
[TBL] [Abstract][Full Text] [Related]
32. Ketamine in depression and electroconvulsive therapy.
Rozet I
Curr Opin Anaesthesiol; 2021 Oct; 34(5):556-562. PubMed ID: 34435599
[TBL] [Abstract][Full Text] [Related]
33. Long-term safety of ketamine and esketamine in treatment of depression.
Nikayin S; Murphy E; Krystal JH; Wilkinson ST
Expert Opin Drug Saf; 2022 Jun; 21(6):777-787. PubMed ID: 35416105
[TBL] [Abstract][Full Text] [Related]
34. What clinicians need to know about intranasal esketamine for treatment-resistant depression?
Hope J; Copolov D; Tiller J; Galbally M; Hopwood M; Newton R; Keks NA
Australas Psychiatry; 2023 Dec; 31(6):841-845. PubMed ID: 37961848
[TBL] [Abstract][Full Text] [Related]
35. R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects.
Yang C; Shirayama Y; Zhang JC; Ren Q; Yao W; Ma M; Dong C; Hashimoto K
Transl Psychiatry; 2015 Sep; 5(9):e632. PubMed ID: 26327690
[TBL] [Abstract][Full Text] [Related]
36. Short-term ketamine administration in treatment-resistant depression: focus on cardiovascular safety.
Szarmach J; Cubała WJ; Włodarczyk A; Wiglusz MS
Psychiatr Danub; 2019 Sep; 31(Suppl 3):585-590. PubMed ID: 31488795
[TBL] [Abstract][Full Text] [Related]
37. Antidepressant Actions of Ketamine: Potential Role of L-Type Calcium Channels.
Robinson B; Gu Q; Kanungo J
Chem Res Toxicol; 2021 May; 34(5):1198-1207. PubMed ID: 33566591
[TBL] [Abstract][Full Text] [Related]
38. Risks Associated with Misuse of Ketamine as a Rapid-Acting Antidepressant.
Zhu W; Ding Z; Zhang Y; Shi J; Hashimoto K; Lu L
Neurosci Bull; 2016 Dec; 32(6):557-564. PubMed ID: 27878517
[TBL] [Abstract][Full Text] [Related]
39. Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2).
Wajs E; Aluisio L; Holder R; Daly EJ; Lane R; Lim P; George JE; Morrison RL; Sanacora G; Young AH; Kasper S; Sulaiman AH; Li CT; Paik JW; Manji H; Hough D; Grunfeld J; Jeon HJ; Wilkinson ST; Drevets WC; Singh JB
J Clin Psychiatry; 2020 Apr; 81(3):. PubMed ID: 32316080
[TBL] [Abstract][Full Text] [Related]
40. Comparison of ketamine, 7,8-dihydroxyflavone, and ANA-12 antidepressant effects in the social defeat stress model of depression.
Zhang JC; Yao W; Dong C; Yang C; Ren Q; Ma M; Han M; Hashimoto K
Psychopharmacology (Berl); 2015 Dec; 232(23):4325-35. PubMed ID: 26337614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
